Novel biomarkers added to movement disorders profile: Andrew McKeon, M.B., B.Ch., M.D.

Answers from the Lab

(00:32)
Can you tell our audience a little bit about yourself and your role here at Mayo Clinic?

(01:29)
Can you tell our listeners a little bit about the disease state when we talk about autoimmune or paraneoplastic movement disorders?

(02:37)
Are we seeing an increased prevalence of autoimmune movement disorders?

(04:00)
Can you give our listeners an overview of what's going to be launched here in January?

(06:56)
What other antibodies are particularly important in this phenotype?

(10:01)
How does the kelch-like protein 11 phenotype manifest in this disorder?

(10:49)
Are there any antibodies in the autoimmune neurology space that would not need to be evaluated for in patients that present with some sort of movement disorder?

(11:18)
Which patients should have this testing and when should it be performed?

(12:55)
When should Mayo Clinic Laboratories' stiff person evaluation and standalone glycine receptor tests be used, and in what order?

(14:40)
Is the movement disorder evaluation the right first choice when the patient presentation is less typical and includes ataxia?

(16:42)
Can physicians order the glycine receptor standalone test to fully evaluate the spectrum of antibodies?

(18:39)
How does the evaluation impact patient care?

(20:12)
Have these new antibodies been shown to be immunotherapy-responsive?

(20:27)
Is there a key takeaway with the launch of these new antibodies in the movement disorder evaluation?